Cargando…

Potassium management with finerenone: Practical aspects

INTRODUCTION: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes. METHODS: Two large, randomized trials have evaluated the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wanner, Christoph, Fioretto, Paola, Kovesdy, Csaba P., Malyszko, Jolanta, Pecoits‐Filho, Roberto, Schnell, Oliver, Rossignol, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659654/ https://www.ncbi.nlm.nih.gov/pubmed/36574588 http://dx.doi.org/10.1002/edm2.360

Ejemplares similares

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference
por: Lindner, Gregor, et al.
Publicado: (2020)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology
por: Rossignol, Patrick
Publicado: (2019)

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Rossing, Peter, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

Enantioselective Total Synthesis of (−)‐Finerenone Using Asymmetric Transfer Hydrogenation
por: Lerchen, Andreas, et al.
Publicado: (2020)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Acid–base balance in hemodialysis patients in everyday practice
por: Wieliczko, Monika, et al.
Publicado: (2022)

Selected Legal Aspects of Donation After Circulatory Death in Poland
por: Guzik-Makaruk, Ewa M., et al.
Publicado: (2019)

Low Serum Potassium Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis Patients: A Propensity-Matched Score Study
por: Ribeiro, Silvia Carreira, et al.
Publicado: (2015)

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients
por: Brunelli, Steven M, et al.
Publicado: (2018)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
por: Shaikh, Aisha, et al.
Publicado: (2022)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone
por: Pollard, Celina M, et al.
Publicado: (2022)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
por: Lv, Ruolin, et al.
Publicado: (2023)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
por: Ashjian, Emily, et al.
Publicado: (2023)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
por: Quist, Sara W., et al.
Publicado: (2023)

Predialysis Potassium Variability and Postdialysis Mortality in Patients With Advanced CKD
por: Dashputre, Ankur A., et al.
Publicado: (2021)

Peritoneal dialysis modality transition and impact on phosphate and potassium serum levels
por: Peruzzo, Daniela, et al.
Publicado: (2021)

The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial
por: Willigers, Bartholomeus J. A., et al.
Publicado: (2023)

SOME CHEMICAL ASPECTS OF THE POTASSIUM EFFECT
por: Osterhout, W. J. V.
Publicado: (1940)

Cannot write session to /tmp/vufind_sessions/sess_792tgjmt3d1mqlr6k114iiuhij